MINJUVI 200 mg, powder for concentrate for infusion bottle
Active ingredients: Tafasitamab
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for concentrate for infusionbottleintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MINJUVI 200 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 200 mg
- Marketing authorisation holder
- INCYTE BIOSCIENCES DISTRIBUTION (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Jan 2022
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65488266CIP75508337CIP133400955083375Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TAFASITAMABpoudre | 200 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.